DIH Holdings US, Inc Class A (DHAI) AI Stock Analysis

68 Followers

DIH Holdings US, Inc Class A

(Other OTC:DHAI)

Select Model

Rating:40Underperform

Price Target:$0.03▲(28900.00% Upside)

Action:reiterated

Date:12/19/25

The overall score is very low primarily because of extremely weak financial performance marked by chronic losses, negative equity, and deteriorating cash flows, compounded by highly adverse corporate events including Nasdaq delisting, operational suspension, and full CEO departure; neutral technicals and a fragile, loss‑driven valuation offer little offset to these substantial risks.

Positive Factors

Strong gross marginsGross margins in the low-50% range provide a durable cushion versus peers and input cost swings. Strong unit economics mean the business can reach operating profitability if SG&A and R&D spend are reined in, supporting margin sustainability over months.

Negative Factors

Consistently negative stockholders' equityA persistent negative shareholders' equity position is a structural solvency concern that limits borrowing capacity, weakens creditor confidence, and heightens refinancing and covenant risk. This condition materially reduces financial flexibility absent a capital raise or sustained profits.

DIH Holdings US, Inc Class A (DHAI) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $837
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.0
Beta (1Y): -18.01
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 178
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

DIH Holdings US, Inc Class A Business Overview & Revenue Model

Company Description

DIH Holding US, Inc. is a company that provides advanced robotics and virtual reality technologies, primarily serving the rehabilitation and human performance sectors. This firm's main office is situated in Norwell, Massachusetts.

How the Company Makes Money

null

DIH Holdings US, Inc Class A Financial Statement Overview

Summary

Financial performance is at the bottom of the scale given persistent operating and net losses, sharply negative EBIT and EBITDA margins, worsening free cash flow, and a balance sheet with sustained negative equity, all indicating severe solvency and going‑concern risk.

Income Statement

27Negative

Balance Sheet

18Very Negative

Cash Flow

16Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Jun 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	62.86M	62.86M	64.47M	55.00M	49.04M	47.52M
Gross Profit	32.03M	32.21M	29.77M	34.54M	24.77M	28.23M
EBITDA	-7.11M	-7.11M	-6.20M	652.00K	-7.83M	-9.63M
Net Income	-8.68M	-8.68M	-8.44M	-2.36M	-12.05M	-10.85M
Balance Sheet
Total Assets	26.75M	26.75M	35.73M	35.73M	34.02M	38.78M
Cash, Cash Equivalents and Short-Term Investments	1.94M	1.94M	3.23M	3.23M	3.31M	3.16M
Total Debt	11.96M	11.96M	15.95M	15.95M	23.63M	17.09M
Total Liabilities	63.89M	63.89M	68.28M	68.28M	60.44M	54.96M
Stockholders Equity	-37.13M	-37.13M	-32.55M	-32.55M	-26.42M	-16.18M
Cash Flow
Free Cash Flow	-4.68M	-4.68M	4.99M	6.02M	-1.71M	-5.74M
Operating Cash Flow	-4.14M	-4.14M	5.19M	6.18M	-744.00K	-4.99M
Investing Cash Flow	-536.00K	-536.00K	-202.00K	-163.00K	-969.00K	-1.12M
Financing Cash Flow	3.39M	3.39M	-4.95M	-3.66M	2.04M	2.16M

DIH Holdings US, Inc Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DHAI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SSKN	43Neutral	$589	0.00	-268.41%	―	-8.54%	40.91%
PAVM	42Neutral	$12.47M	-0.10	-33.51%	―	-89.02%	-107.75%
HSCS	40Underperform	$11.90M	-0.72	-816.25%	―	-27.70%	61.44%
DHAI	40Underperform	$837	0.00	24.90%	―	―	―
BMRA	38Underperform	$6.81M	-0.93	-142.81%	―	-11.20%	-6.64%
TNON	30Underperform	$4.68M	-0.04	-547.15%	―	80.25%	77.34%

* Healthcare Sector Average

Performance Comparison

DHAI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DHAI	DIH Holdings US, Inc Class A	0.02	0.00	0.00%
SSKN	Strata Skin Sciences	0.09	-1.27	-93.38%
BMRA	Biomerica Inc	1.51	-0.90	-37.34%
PAVM	Pavmed	1.60	-7.99	-83.28%
TNON	Tenon Medical, Inc.	1.75	-39.55	-95.77%
HSCS	Heart Test Laboratories, Inc.	2.29	-0.77	-25.24%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Mar 24, 2026

DIH Holdings US, Inc Class A AI Stock Analysis